Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $50 Price Target

Benzinga · 10/18 11:56
Cantor Fitzgerald analyst Olivia Brayer reiterates Bristol-Myers Squibb (NYSE:BMY) with a Neutral and maintains $50 price target.